Where did the figures re stroke percentages come from.I can't recall seeing these during the trial or the prolonged delay awaiting approval.Trading outside USA don't appear to support these alarming claims.The complete trial & time taken after indicate a very sloppy performance and to say the least the FDA must lift their game.
